Neuronetics Inc (STIM) - Total Liabilities
Based on the latest financial reports, Neuronetics Inc (STIM) has total liabilities worth $108.38 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Neuronetics Inc - Total Liabilities Trend (2016–2025)
This chart illustrates how Neuronetics Inc's total liabilities have evolved over time, based on quarterly financial data. See working capital position of Neuronetics Inc to evaluate short-term liquidity relative to the company's equity base.
Neuronetics Inc Competitors by Total Liabilities
The table below lists competitors of Neuronetics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sucro Limited
V:SUGR
|
Canada | CA$515.60 Million |
|
Kingcan Holdings Ltd
TW:8411
|
Taiwan | NT$7.27 Billion |
|
Gowing Bros Ltd
AU:GOW
|
Australia | AU$132.17 Million |
|
Daehan Synthet
KO:003830
|
Korea | ₩127.57 Billion |
|
Phillips 66
F:PSX
|
Germany | €148.10 Million |
|
Immutep Ltd ADR
NASDAQ:IMMP
|
USA | $48.30 Million |
|
Hanil Iron & S
KO:002220
|
Korea | ₩177.66 Billion |
|
Dual Co Ltd
KO:016740
|
Korea | ₩269.69 Billion |
Liability Composition Analysis (2016–2025)
This chart breaks down Neuronetics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Neuronetics Inc worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.67 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 8.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.86 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Neuronetics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Neuronetics Inc (2016–2025)
The table below shows the annual total liabilities of Neuronetics Inc from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $115.31 Million | +5.69% |
| 2024-12-31 | $109.10 Million | +33.64% |
| 2023-12-31 | $81.64 Million | +36.47% |
| 2022-12-31 | $59.82 Million | +6.74% |
| 2021-12-31 | $56.05 Million | +5.42% |
| 2020-12-31 | $53.16 Million | +1.62% |
| 2019-12-31 | $52.32 Million | +13.78% |
| 2018-12-31 | $45.98 Million | -80.15% |
| 2017-12-31 | $231.59 Million | +14.69% |
| 2016-12-31 | $201.92 Million | -- |
About Neuronetics Inc
Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company provides NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a p… Read more